VeriLuce Therapeutics is a research and discovery/early-stage drug development Company focusing on designing and developing novel small molecules antagonizing two receptors within the immune-tumor micro-environment in dualistic mode in order to slow down/stop cancer growth; the two receptor targets belong to the GPCR chemokine receptor family. By targeting the two specific chemokine receptors, we believe that the tumor micro-environment will be modified so as to favour increased tumor cells killing and metastasis. Targeting chemokine receptors in dual antagonistic fashion is more potent, more efficacious and less prone to side effects creation than targeting receptors in single antagonistic mode.

VeriLuce Therapeutics Logo



Event details

Date: June 13 - 16, 2022

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


26 in total